Reaction
Nasal Ulcer reporting signals
As of the last recalculation, Nasal Ulcer appears in 1,581 FAERS reports alongside 30 co-occurring drug terms. The strongest observed disproportionality signal is DESLORATADINE (PRR 37.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Desloratadine | 30 | 37.5 | 37.6 |
| Cabozantinib | 101 | 29.5 | 29.6 |
| Drs. Clotrimazole | 25 | 28.9 | 29.0 |
| Family Wellness Clotrimazole | 25 | 28.9 | 29.0 |
| Clotrimazole Topical | 25 | 28.9 | 29.0 |
| Clotrimazole | 26 | 28.3 | 28.4 |
| Ketoconazole | 29 | 22.4 | 22.5 |
| Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hcl | 73 | 20.1 | 20.1 |
| Erlotinib | 10 | 13.7 | 13.7 |
| Fluticasone Propionate | 119 | 13.0 | 13.0 |
| Lapatinib | 15 | 12.8 | 12.9 |
| Erlotinib Hydrochloride | 12 | 12.7 | 12.7 |
| Rosuvastatin Calcium | 26 | 12.3 | 12.3 |
| Pertuzumab | 23 | 11.3 | 11.3 |
| Baricitinib | 8 | 11.0 | 11.0 |
| Peginterferon Alfa-2A | 38 | 9.5 | 9.5 |
| Panitumumab | 11 | 9.3 | 9.3 |
| Tocilizumab | 73 | 8.8 | 8.8 |
| Diclofenac Potassium | 7 | 8.6 | 8.6 |
| Tofacitinib Citrate | 8 | 8.1 | 8.1 |
| Trastuzumab | 39 | 7.6 | 7.6 |
| Belimumab | 15 | 6.3 | 6.3 |
| Ibrutinib | 37 | 6.2 | 6.2 |
| Golimumab | 33 | 5.2 | 5.2 |
| Cannabidiol | 9 | 5.1 | 5.1 |
| Ribavirin | 24 | 5.0 | 5.0 |
| Voclosporin | 3 | 4.6 | 4.6 |
| Lenvatinib | 10 | 4.0 | 4.0 |
| Esketamine Hydrochloride | 5 | 3.7 | 3.7 |
| Erenumab-Aooe | 8 | 1.9 | 1.9 |